# Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors

> **NCT01428427** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 31 (actual)

## Conditions studied

- Leukaemia, Myelocytic, Acute

## Interventions

- **DRUG:** GSK1120212
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01428427
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-12
- **Primary completion:** 2011-07-18
- **Final completion:** 2011-07-18
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428427, "Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01428427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*